Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia
OBJECTIVES:
- To promote harmonization between Cooperative Group Reference Laboratories conducting
minimal-residual disease (MRD) evaluation of acute myeloid leukemia by flow cytometry.
OUTLINE: Archived bone marrow and blood samples, distributed to the Eastern Cooperative
Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B laboratories, are
analyzed for leukemia-associated immunophenotype (LAIP) assays and minimal residual disease
studies by flow cytometry. Results are then provided to the National Cancer Institute for
assessment and comparability of test results.
Observational
N/A
Degree of concordance in the MRD assay results between laboratories
No
J. Milburn Jessup, MD
Principal Investigator
National Cancer Institute (NCI)
United States: Federal Government
CDR0000720362
NCT01498302
February 2012
Name | Location |
---|